All Stories

  1. Allergic broncho‐pulmonary aspergillosis: Old disease, new frontiers
  2. Endoplasmic reticulum stress enhances the expression of TLR3-induced TSLP by airway epithelium
  3. Mapping the Common Barriers to Optimal COPD Care in High and Middle-Income Countries: Qualitative Perspectives from Clinicians
  4. Biologic therapies for severe asthma with persistent type 2 inflammation
  5. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia
  6. Cough in Children and Adults: Diagnosis, Assessment and Management (CICADA). Summary of an updated position statement on chronic cough in Australia
  7. Large airway wall vascularity in patients with Asthma COPD overlap: a bronchoscopy study
  8. Mapping the common barriers to optimal COPD care in high and middle-income countries: qualitative perspectives from clinicians
  9. Inflammatory and antiviral responses to influenza A virus infection are dysregulated in pregnant mice with allergic airway disease
  10. Upper Respiratory Tract OC43 Infection Model for Investigating Airway Immune-modifying Therapies
  11. Mechanical forces suppress antiviral innate immune responses from asthmatic airway epithelial cells following rhinovirus infection
  12. Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist
  13. Saline at lower tonicity in CF (SALTI-CF) trial comparing 0.9% v 3% v 6% nebulised saline
  15. Comparative B cell and antibody responses induced by adenoviral vectored and mRNA vaccines against COVID-19
  16. Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics
  17. Comparison of commercially available differentiation media on morphology, function, and virus-host interaction in conditionally reprogrammed human bronchial epithelial cells
  18. A systematic review of the colorectal microbiome in adult cystic fibrosis patients
  19. Probiotic Bifidobacterium longum subsp. longum Protects against Cigarette Smoke-Induced Inflammation in Mice
  20. Survival of people with cystic fibrosis in Australia
  21. Conditionally reprogrammed asthmatic bronchial epithelial cells express lower FOXJ1 at terminal differentiation and lower IFNs following RV-A1 infection
  22. Obesity and COVID-19 Disease: To Inflame or Not
  23. Association between dietary fibre, microbial metabolites and airway obstruction in COPD patients and murine models
  24. Crucial role of iron metabolism in determining outcomes of influenza A virus infection and disease
  25. Histone deacetylase-6 (HDAC6) promotes protective responses during murine influenza A virus (IAV) infection
  26. Hydrogen sulfide attenuates cigarette smoke-induced oxidative stress and inflammation in human primary bronchial epithelial cells and experimental COPD
  27. Relationship between interleukin-13 and transferrin receptor-1 responses in the pathogenesis of asthma
  28. Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis
  29. We need to understand why viral infections lead to acute asthma
  30. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
  31. IL-25 blockade augments antiviral immunity during respiratory virus infection
  32. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network FluCAN
  33. Mental health care needs in cystic fibrosis: A scoping review
  34. Understanding motivation for Australian adolescents and young adults with cystic fibrosis: Modifiable factors to support self‐management
  35. Pathogenesis, clinical features of asthma COPD overlap, and therapeutic modalities
  36. Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN)
  37. Factors Associated with Asthma Exacerbations During Pregnancy
  38. Increased cough, mucus and wheeze characterise COPD and Asthma in Australian Aboriginal adults
  39. We are not doing enough to prevent the spread of COVID‐19 and other respiratory viruses in Australian hospitals
  40. Transcriptomics of biopsies identifies novel genes and pathways linked to neutrophilic inflammation in severe asthma
  41. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights
  42. Dysregulated actin cytoskeleton associated with barrier dysfunction in asthma
  43. Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
  44. Redesign of the Australian Cystic Fibrosis Data Registry: A multidisciplinary collaboration
  45. Asthma-COPD overlap: current understanding and the utility of experimental models
  46. ACE2 expression is elevated in airway epithelial cells from older and male healthy individuals but reduced in asthma
  47. Dysregulation of endocytic machinery and ACE2 in small airways of smokers and COPD patients can augment their susceptibility to SARS-CoV-2 (COVID-19) infections
  48. Hemopexin: A Novel Anti-inflammatory Marker for Distinguishing COPD From Asthma
  49. TLR2-mediated innate immune priming boosts lung anti-viral immunity
  50. Molecular and Immunological Mechanisms Underlying the Various Pharmacological Properties of the Potent Bioflavonoid, Rutin
  51. Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells
  52. Curcumin-loaded niosomes downregulate mRNA expression of pro-inflammatory markers involved in asthma: an in vitro study
  53. Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization
  54. Australian cystic fibrosis community views on organoids
  55. PAT in the ER for Transmembrane Protein Folding
  56. Severe Nocardia pneumonia in an immunocompromised patient with alpha‐1 antitrypsin deficiency
  57. Omalizumab is an effective intervention in severe asthma with aspergillus sensitisation
  58. Managing T2-High Inflammation in Severe Asthma - Are Biomarkers Better Than Clinician Judgement?
  59. Late Breaking Abstract - ACE2 expression in lower airway epithelial cells is increased with age and in males, but is less in asthma
  60. ACE2 Expression is elevated in Airway Epithelial Cells from aged and male donors but reduced in asthma
  61. A Sputum 6 Gene Expression Signature Predicts Inflammatory Phenotypes and Future Exacerbations of COPD
  62. Molecular mechanisms of action of naringenin in chronic airway diseases
  63. Celastrol-loaded liquid crystalline nanoparticles as an anti-inflammatory intervention for the treatment of asthma
  64. Asthma and the Dysregulated Immune Response to Rhinovirus
  65. Management of acute COPD exacerbations in Australia: do we follow the guidelines?
  66. A survey of specialist opinions on biomarker use in severe asthma in Australia: scepticism but hope?
  67. Contemporary Concise Review 2019: Asthma
  68. Diagnosis and treatment of lung disease associated with alpha one‐antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand*
  69. Immunological axis of berberine in managing inflammation underlying chronic respiratory inflammatory diseases
  70. Six gene and TH2 signature expression in endobronchial biopsies of participants with asthma
  71. Sputum transcriptomics implicates increased p38 signalling activity in severe asthma
  72. Targeting treatable traits in severe asthma: a randomised controlled trial
  73. Antiviral immunity is impaired in COPD patients with frequent exacerbations
  74. Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease
  75. Preparation, characterization and in-vitro efficacy of quercetin loaded liquid crystalline nanoparticles for the treatment of asthma
  76. Nasal epithelial cells to assess in vitro immune responses to respiratory virus infection in pregnant women with asthma
  77. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)
  78. Blood Neutrophils In COPD But Not Asthma Exhibit A Primed Phenotype With Downregulated CD62L Expression
  79. Hypoxia‐inducible factor and bacterial infections in chronic obstructive pulmonary disease
  80. People with asthma are more likely to become ill from influenza
  81. A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis
  82. Asthmatic airway epithelial cells subjected to apical mechanical stress exhibit suppressed interferon release following viral infection
  83. Circulatory neutrophils in COPD feature downregulated CD62L expression in comparison with asthma and healthy participants
  84. Inhibition of ER stress suppresses IL-13 induced airway epithelial remodeling
  85. Endobronchial biopsy gene expression between different severe asthma inflammatory phenotypes
  86. Treatment with Omalizumab in adults with severe allergic reduces Fc?I expression on dendritic cells and improves antiviral responses
  87. Sputum gene signature comparison study between U-BIOPRED and Australia asthma cohorts
  88. Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)
  89. Fibulin-1c regulates transforming growth factor–β activation in pulmonary tissue fibrosis
  90. RIPLET, and not TRIM25, is required for endogenous RIG‐I‐dependent antiviral responses
  91. Respiratory syncytial virus co-opts host mitochondrial function to favour infectious virus production
  92. Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
  93. IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis
  94. Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome
  95. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report
  96. The importance of acute asthma.
  97. CSF3R/CD114 mediates infection-dependent transition to severe asthma
  98. Hypersegmented airway neutrophils and its association with reduced lung function in adults with obstructive airway disease: an exploratory study
  99. Molecular modulators of celastrol as the keystones for its diverse pharmacological activities
  100. Enhancing tristetraprolin activity reduces the severity of cigarette smoke‐induced experimental chronic obstructive pulmonary disease
  101. The interplay of the host, virus, and the environment
  102. Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma
  103. Multi-Centre Ethics and Research Governance Review Can Impede Non-Interventional Clinical Research
  104. Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease
  105. Nebulised hypertonic saline for cystic fibrosis
  106. Treatable traits can be identified in a severe asthma registry and predict future exacerbations
  107. Mechanisms of impaired anti-bacterial Th1 responses in patients with chronic obstructive pulmonary disease
  108. Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors
  109. Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration
  110. Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics
  111. Appropriate use of oral corticosteroids for severe asthma
  112. Effects of fruit and vegetable consumption on inflammatory biomarkers and immune cell populations: a systematic literature review and meta-analysis
  113. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations
  114. Trends in asthma self-management skills and inhaled corticosteroid use during pregnancy and postpartum from 2004 to 2017
  115. Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches
  116. Developments in cystic fibrosis personalised epithelial assays: Science and patient perspectives
  117. Pseudomonas pharyngitis in a cystic fibrosis patient
  118. Immunological axis of curcumin-loaded vesicular drug delivery systems
  119. Impaired Th1 responses in patients with acute exacerbations of COPD are improved with PD-1 blockade
  120. Understanding the Unfolded Protein Response in the Pathogenesis of Asthma
  121. Respiratory Viruses and Asthma
  122. Eosinophilia as a treatable trait in three patients with asthma and COPD
  123. Pathophysiology of severe asthma: We’ve only just started
  124. Systematic review and website presentation of validated dietary assessment tools
  125. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c
  128. A new website to support dietary assessment in health research:
  129. Treatment burden, clinical outcomes, and comorbidities in COPD: an examination of the utility of medication regimen complexity index in COPD
  130. Multidimensional assessment and targeted therapy of severe asthma: a randomised controlled trial (RCT)
  131. A transcriptomic comparison between nasal and bronchial airway epithelia from children
  132. Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells
  133. Role for NLRP3 Inflammasome–mediated, IL-1β–Dependent Responses in Severe, Steroid-Resistant Asthma
  134. MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD
  135. Effects of Fruit and Vegetable Consumption on Risk of Asthma, Wheezing and Immune Responses: A Systematic Review and Meta-Analysis
  136. Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling
  137. Role of miR-218 in COPD
  138. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)
  139. Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
  140. Severe asthma: Current management, targeted therapies and future directions-A roundtable report
  141. Acute myocardial infarction in disseminated mucormycosis infection
  142. The genetic and epigenetic landscapes of the epithelium in asthma
  143. A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics
  144. Effect of oxidative stress and rhinovirus infection on mitochondrial/endoplasmic reticular function in human primary bronchial epithelial cells
  145. Micro-RNA-125a/b target A20 and MAVS to promote inflammatory and impair antiviral responses in chronic obstructive pulmonary disease
  146. NLRP3 inflammasome-mediated, IL-1β-dependent inflammatory responses drive steroid-resistant asthma
  147. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
  148. Recent advances in understanding and managing asthma
  149. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD
  150. Impaired Antiviral Stress Granule and IFN-β Enhanceosome Formation Enhances Susceptibility to Influenza Infection in Chronic Obstructive Pulmonary Disease Epithelium
  151. What is asthma−COPD overlap syndrome? Towards a consensus definition from a round table discussion
  152. Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases
  153. Advances in the treatment of virus-induced asthma
  154. Acute oxygen therapy: a review of prescribing and delivery practices
  155. Targeted therapeutics for severe refractory asthma: monoclonal antibodies
  156. Diagnosis and investigation in the severe asthma clinic
  157. A randomised trial of hypertonic saline during hospitalisation for exacerbation of cystic fibrosis
  158. Innate Immunity and Immune Evasion by Enterovirus 71
  159. Influenza vaccine effectiveness against hospitalisation with influenza in adults in Australia in 2014
  160. A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease
  161. Can blood eosinophils predict sputum eosinophils in stable COPD?
  162. Potential role of SPARC, a downstream mediator of TGF-b in chronic airways disease
  163. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma
  164. The social network of cystic fibrosis centre care and shared Pseudomonas aeruginosa strain infection: a cross-sectional analysis
  165. Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia
  166. Targeting PI3K-p110α Suppresses Influenza Virus Infection in Chronic Obstructive Pulmonary Disease
  167. The Placental Protein Syncytin-1 Impairs Antiviral Responses and Exaggerates Inflammatory Responses to Influenza
  168. CD8 T cells and dendritic cells: key players in the attenuated maternal immune response to influenza infection
  169. World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance
  170. Airwayβ-Defensin-1 Protein Is Elevated in COPD and Severe Asthma
  171. 81
  172. 82
  173. 175
  174. 147
  175. Differential injurious effects of ambient and traffic-derived particulate matter on airway epithelial cells
  176. How the placenta makes pregnant women vulnerable to influenza (Flu)
  177. PP38 Development of a new UK food composition database
  178. The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial
  179. Cough Formation in Viral Infections in Children
  180. The interaction between mother and fetus and the development of allergic asthma
  181. TLR3 and MDA5 signalling, although not expression, is impaired in asthmatic epithelial cells in response to rhinovirus infection.
  182. A Prospective Study of Respiratory Viral Infection in Pregnant Women With and Without Asthma
  183. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission
  184. Influenza Vaccine Effectiveness against Hospitalisation with Confirmed Influenza in the 2010–11 Seasons: A Test-negative Observational Study
  185. Plasmacytoid Dendritic Cells and CD8 T Cells From Pregnant Women Show Altered Phenotype and Function Following H1N1/09 Infection
  186. Alterations in inflammatory, antiviral and regulatory cytokine responses in peripheral blood mononuclear cells from pregnant women with asthma
  187. Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease
  188. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis
  189. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity
  190. Novel immune genes associated with excessive inflammatory and antiviral responses to rhinovirus in COPD
  191. Deficient antiviral responses to influenza in primary bronchial epithelial cells of chronic obstructive pulmonary disease
  192. Innate immunity to influenza in chronic airways diseases
  193. RAGE: a new frontier in chronic airways disease
  194. SharedPseudomonas aeruginosagenotypes are common in Australian cystic fibrosis centres
  195. Viral infections trigger exacerbations of cystic fibrosis in adults and children: Figure 1–
  196. Pregnant Women Have Attenuated Innate Interferon Responses to 2009 Pandemic Influenza A Virus Subtype H1N1
  197. Characteristics of a Widespread Community Cluster of H275Y Oseltamivir-Resistant A(H1N1)pdm09 Influenza in Australia
  198. Multicentre audit of inpatient management of acute exacerbations of chronic obstructive pulmonary disease: comparison with clinical guidelines
  199. Airway inflammation in asthma, a single measurement is not enough
  200. Glucocorticosteroids Differentially Regulate MMP-9 and Neutrophil Elastase in COPD
  201. Critical Role of Constitutive Type I Interferon Response in Bronchial Epithelial Cell to Influenza Infection
  202. Serum amyloid A opposes lipoxin A 4 to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease
  203. Clinical and physiological features of postinfectious chronic cough associated with H1N1 infection
  204. Developments in the field of allergy in 2010 through the eyes of Clinical and Experimental Allergy
  205. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study
  206. Soluble RAGE is deficient in neutrophilic asthma and COPD
  207. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma
  208. P2-316 Adult height in relation to cancer mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort
  209. Tiotropium reduced exacerbations more than salmeterol in moderate-to-very severe COPD
  210. Human Influenza Is More Effective than Avian Influenza at Antiviral Suppression in Airway Cells
  211. A Novel E3 Ubiquitin Ligase Links Rhinovirus Infection To Exacerbation Of Asthma
  212. Respiratory Examination
  213. Characterization of innate immune signalling receptors in virus-induced acute asthma
  214. Antioxidant and Anti-Inflammatory Effects of Resveratrol in Airway Disease
  215. Down-titration from high-dose combination therapy in asthma: Removal of long-acting β2-agonist
  216. Viral and bacterial interactions in pneumonia
  217. TLR5 is not required for flagellin-mediated exacerbation of DSS colitis
  218. Asthma during pregnancy alters immune cell profile and airway epithelial chemokine release
  219. Lycopene enrichment of cultured airway epithelial cells decreases the inflammation induced by rhinovirus infection and lipopolysaccharide
  220. Nebulised hypertonic saline for cystic fibrosis
  221. Low Rates of Pseudomonas aeruginosa Misidentification in Isolates from Cystic Fibrosis Patients
  222. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains
  223. Pathogenesis of ABPA
  224. Guest Editorial
  225. Innate immune response to viral infection of the lungs
  226. Flagellin exacerbates DSS induced Colitis via TLR5 independent mechanisms
  228. Anti-inflammatory effects of long-chain n-3 PUFA in rhinovirus-infected cultured airway epithelial cells
  229. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii
  230. Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages
  231. The role of exhaled nitric oxide and exhaled breath condensates in evaluating airway inflammation in asthma
  232. Understanding the mechanisms of viral induced asthma: New therapeutic directions
  233. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease
  234. IFN-γ–induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations
  235. Asthma exacerbations {middle dot} 3: Pathogenesis
  236. Role of deficient type III interferon-λ production in asthma exacerbations
  237. Nebulised hypertonic saline for cystic fibrosis
  238. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus
  239. Induced Sputum 8-Isoprostane Concentrations in Inflammatory Airway Diseases
  240. Pathogenesis of allergic bronchopulmonary aspergillosis and an evidence-based review of azoles in treatment
  241. Hyperkalaemic ascending paralysis
  242. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial
  243. Use of induced sputum for the diagnosis of influenza and infections in asthma: a comparison of diagnostic techniques
  244. Airway inflammation in thunderstorm asthma
  245. Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma
  246. Optimization of sputum-processing methods for the measurement of interleukin-5: Effects of protease inhibition
  247. Non-invasive ventilation in acute respiratory failure
  248. Safety of sputum induction with isotonic saline in adults with acute severe asthma
  249. Allergic bronchopulmonary aspergillosis: New concepts of pathogenesis and treatment
  250. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma
  251. Induced sputum eosinophils and neutrophils and bronchiectasis severity in allergic bronchopulmonary aspergillosis
  252. Induced sputum eosinophils in the assessment of asthma and chronic cough*
  253. Bronchitis
  254. Difficult Asthma
  255. Non-Invasive Ventilation in Acute Respiratory Failure